ArticleEndocrine2019
Novel high molecular weight albumin-conjugated angiotensin II activates β-arrestin and G-protein pathways.
Article in Endocrine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 6 citations in OpenAlex.
- Insights Into the Role of Angiotensin-II ATHypertension (Dallas, Tex. : 1979) · 2024Review
- ARRB2 (β-Arrestin-2) Deficiency Alters Fluid Homeostasis and Blood Pressure Regulation.Hypertension (Dallas, Tex. : 1979) · 2022Article
- From Agonist to Antagonist: Modulation of the Physiological Action of Angiotensins by Protein Conjugation-Hemodynamics and Behavior.Frontiers in pharmacology · 2021Article
- Downregulation of Brain Gα12 Attenuates Angiotensin II-Dependent Hypertension.American journal of hypertension · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 1 country.
Funding
Abstract
purposeTo study the ability of a novel bovine serum albumin-angiotensin II (BSA-Ang II) conjugate to effect responses of the AT
methodsAngiotensin II (Ang II) was conjugated with bovine serum albumin and compared with Ang II for competition binding to AT
resultsThe BSA-Ang II conjugate was less potent competing for AT
conclusionsAddition of a high molecular weight molecule to Ang II reduced its AT
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.